TNXP Stock Overview
A biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Tonix Pharmaceuticals Holding Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.16 |
| 52 Week High | US$2.10 |
| 52 Week Low | US$0.12 |
| Beta | 2.17 |
| 1 Month Change | -11.72% |
| 3 Month Change | -55.37% |
| 1 Year Change | -91.82% |
| 3 Year Change | -99.94% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Tonix stock rises on FDA nod to start trial of TNX-601 for depression
Oct 03Tonix Pharmaceuticals GAAP EPS of -$1.22 beats by $0.23
Aug 08Tonix announces partnership to study monkeypox vaccine in 1H 2023
Jul 28Tonix Pharma to develop extended-release form of depression therapy
Jul 11Is Tonix Pharma's Stock A Buy Or Sell After Buyback Plan Announcement?
Jun 21Shareholder Returns
| TNXP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.7% | 0.6% | -0.6% |
| 1Y | -91.8% | 6.3% | 22.4% |
Return vs Industry: TNXP underperformed the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: TNXP underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| TNXP volatility | |
|---|---|
| TNXP Average Weekly Movement | 15.2% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: TNXP's share price has been volatile over the past 3 months.
Volatility Over Time: TNXP's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 103 | Seth Lederman | www.tonixpharma.com |
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates.
Tonix Pharmaceuticals Holding Corp. Fundamentals Summary
| TNXP fundamental statistics | |
|---|---|
| Market cap | US$15.56m |
| Earnings (TTM) | -US$98.59m |
| Revenue (TTM) | US$10.25m |
1.5x
P/S Ratio-0.2x
P/E RatioIs TNXP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TNXP income statement (TTM) | |
|---|---|
| Revenue | US$10.25m |
| Cost of Revenue | US$6.40m |
| Gross Profit | US$3.85m |
| Other Expenses | US$102.44m |
| Earnings | -US$98.59m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.03 |
| Gross Margin | 37.55% |
| Net Profit Margin | -961.87% |
| Debt/Equity Ratio | 8.3% |
How did TNXP perform over the long term?
See historical performance and comparison